Microbiotix, Inc. is a clinical stage biopharmaceutical company focused on discovery and development of proprietary small molecule drugs target ingserious infectious diseases, including multi-drug resistant pathogens The Company's lead program isMBX-400, a novel, potent nucleoside dual DNA polymerase/kinase inhibitor for the management of cytomegalovirus (CMV) disease in transplant patients. The firm also organizes around R&D of small molecule anti-infective drugs for the treatment of infectious diseases. with a focus on hepatitis C virus (HCV) and cytomegalovirus (CMV). Products include MBX-700 and MBX-701 that are irreversible non-nucleoside inhibitors of the hepatitis C virus polymerase; and MBX-400, a potent nucleoside DNA polymerase inhibitor for the treatment of human cytomegalovirus. The company also engages in clinical R&D of antibacterial and antiviral discovery programs in the areas of filovirus, malaria, gram-negative bacterial infections, multi-drug resistant tuberculosis, and influenza. SInce start-up, Microbiotix has had extensive working relationships with various major players inthe space.
